^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ZBTB20-AS4 (ZBTB20 Antisense RNA 4)

    i
    Other names: ZBTB20-AS4, ZBTB20 Antisense RNA 4, ZBTB20 Antisense RNA 4 (Non-Protein Coding), NONHSAG035794.2, HSALNG0028192, ZBTB20-AS4
    Associations

    News

    Trials
    over2years
    Integrative analysis of multi-omics data reveals a pseudouridine-related lncRNA signature for prediction of glioma prognosis and chemoradiotherapy sensitivity. (PubMed, Comput Biol Med)
    Our study identified a four-lncRNA ΨrLs signature that effectively predicts the prognosis of glioma patients and may serve as a diagnostic tool. Risk scores of glioma patients generated by the signature is associated with immune-related biological processes and chemoradiotherapy sensitivity. These findings may inform the development of more targeted and effective therapies for glioma patients.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PTEN (Phosphatase and tensin homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • GDNF-AS1 (GDNF Antisense RNA 1) • ZBTB20-AS4 (ZBTB20 Antisense RNA 4)
    |
    EGFR mutation
    |
    mitoxantrone
    over3years
    A Novel Necroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Response of Glioma. (PubMed, Biomed Res Int)
    Through functional enrichment analyses, we found that the differentially expressed genes (DEGs) were mainly enriched in protein binding and signaling-related biological functions and immune-associated pathways. In conclusion, we established and validated a novel necroptosis-related lncRNA signature, which could accurately predict the overall survival of glioma patients and serve as potential therapeutic targets.
    Journal
    |
    ZBTB20-AS4 (ZBTB20 Antisense RNA 4)